Besides developing formulations for potential new chemical entities, we also work to improving existing Cadila formulations. Our aim is to ensure maximum efficacy for an existing drug, as well as increasing the chances of product compliance by the patient. Developing new ways of administering old drugs to patients often calls for sophisticated knowledge of chemistry, as well as, a sharp understanding and experience of patient behaviour and various compliance factors.

Towards this end, our efforts are consistently targeted at making the delivery of new, as well as old drugs more efficient in order to ensure maximum relief for patients and limit the potential side-effects of any drug.

In the end, Cadila believes that formulation is a data-driven science that must adhere to a laid-down, quality-vetted process. After carefully analysing and understanding a client's specific needs, we create a target product profile (TPP) that is clearly and unambiguously defined before developing any product algorithm.

All these years, we have been very active at devising elaborate strategies for formulations that have been very effective at meeting stringent international quality norms and regulatory practices. This is how we have managed to come up with a huge line of affordable products that also ensure patient compliance.

Cadila has in place a Quality by Design (QBD) approach that uses time-tested Modelling and Design of Experiments (DoE) approach to deliver a strong regulatory package on a product.

Leading from the front, we know from our past experience that in research, no single approach can effectively solve all problems. Therefore, our strategy combines the application of multiple technologies in our drug formulation process.